These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 15569207)

  • 1. Phase II study of weekly paclitaxel for docetaxel-resistant metastatic breast cancer in Japan.
    Taguchi T; Aihara T; Takatsuka Y; Shin E; Motomura K; Inaji H; Noguchi S;
    Breast J; 2004; 10(6):509-13. PubMed ID: 15569207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer.
    Gradishar WJ; Krasnojon D; Cheporov S; Makhson AN; Manikhas GM; Clawson A; Bhar P
    J Clin Oncol; 2009 Aug; 27(22):3611-9. PubMed ID: 19470941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer.
    Gennari A; Guarneri V; Landucci E; Orlandini C; Rondini M; Salvadori B; Ricci S; Conte PF
    Clin Breast Cancer; 2002 Dec; 3(5):346-52. PubMed ID: 12533265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes.
    Blum JL; Savin MA; Edelman G; Pippen JE; Robert NJ; Geister BV; Kirby RL; Clawson A; O'Shaughnessy JA
    Clin Breast Cancer; 2007 Dec; 7(11):850-6. PubMed ID: 18269774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Weekly high-dose paclitaxel in metastatic and locally advanced breast cancer: a preliminary report.
    Akerley W; Sikov WM; Cummings F; Safran H; Strenger R; Marchant D
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-87-S17-90. PubMed ID: 9374102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of weekly paclitaxel for advanced or metastatic breast cancer in Japan.
    Horiguchi J; Rai Y; Tamura K; Taki T; Hisamatsu K; Ito Y; Seriu T; Tajima T
    Anticancer Res; 2009 Feb; 29(2):625-30. PubMed ID: 19331212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252.
    Perez EA; Suman VJ; Rowland KM; Ingle JN; Salim M; Loprinzi CL; Flynn PJ; Mailliard JA; Kardinal CG; Krook JE; Thrower AR; Visscher DW; Jenkins RB
    Clin Breast Cancer; 2005 Dec; 6(5):425-32. PubMed ID: 16381626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer.
    Lee KS; Chung HC; Im SA; Park YH; Kim CS; Kim SB; Rha SY; Lee MY; Ro J
    Breast Cancer Res Treat; 2008 Mar; 108(2):241-50. PubMed ID: 17476588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High efficacy and low toxicity of weekly docetaxel given as first-line treatment for metastatic breast cancer.
    Stemmler J; Mair W; Stauch M; Papke J; Deutsch G; Abenhardt W; Dorn B; Kentenich C; Malekmohammadi M; Jackisch C; Leinung S; Brudler O; Vehling-Kaiser U; Stamp J; Heinemann V
    Oncology; 2005; 68(1):71-8. PubMed ID: 15809523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer.
    Blum JL; Dees EC; Chacko A; Doane L; Ethirajan S; Hopkins J; McMahon R; Merten S; Negron A; Neubauer M; Ilegbodu D; Boehm KA; Asmar L; O'Shaughnessy JA
    J Clin Oncol; 2006 Sep; 24(27):4384-90. PubMed ID: 16926223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paclitaxel combined with ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistance.
    Moon YW; Sohn JH; Choi HJ; Chang H; Park BW; Kim SI; Park S; Koo JS; Kim YT; Roh JK; Chung HC; Kim JH
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):425-31. PubMed ID: 20012956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Weekly docetaxel as second-line therapy for patients with advanced breast cancer resistant to previous anthracycline treatment.
    Ramos M; González-Ageitos A; Amenedo M; González-Quintas A; Gamazo JL; Togores P; Losada G; Almanza C; Romero C; Gómez-Martín C
    J Chemother; 2003 Apr; 15(2):192-7. PubMed ID: 12797398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study.
    Penel N; Bui BN; Bay JO; Cupissol D; Ray-Coquard I; Piperno-Neumann S; Kerbrat P; Fournier C; Taieb S; Jimenez M; Isambert N; Peyrade F; Chevreau C; Bompas E; Brain EG; Blay JY
    J Clin Oncol; 2008 Nov; 26(32):5269-74. PubMed ID: 18809609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Weekly paclitaxel versus weekly docetaxel in elderly or frail patients with metastatic breast carcinoma: a randomized phase-II study of the Belgian Society of Medical Oncology.
    Beuselinck B; Wildiers H; Wynendaele W; Dirix L; Kains JP; Paridaens R
    Crit Rev Oncol Hematol; 2010 Jul; 75(1):70-7. PubMed ID: 19651523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer.
    Burris H; Yardley D; Jones S; Houston G; Broome C; Thompson D; Greco FA; White M; Hainsworth J
    J Clin Oncol; 2004 May; 22(9):1621-9. PubMed ID: 15117984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical and clinical study results of the combination of paclitaxel and 5-fluorouracil/folinic acid in the treatment of metastatic breast cancer.
    Klaassen U; Harstrick A; Wilke H; Seeber S
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):44-7. PubMed ID: 8629037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Weekly paclitaxel--an effective treatment for advanced breast cancer.
    Kellokumpu-Lehtinen P; Tuunanen T; Asola R; Elomaa L; Heikkinen M; Kokko R; Järvenpää R; Lehtinen I; Maiche A; Kaleva-Kerola J; Huusko M; Möykkynen K; Ala-Luhtala T
    Anticancer Res; 2013 Jun; 33(6):2623-7. PubMed ID: 23749918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study of three-weekly docetaxel and weekly trastuzumab in HER2-overexpressing advanced breast cancer.
    Montemurro F; Choa G; Faggiuolo R; Donadio M; Minischetti M; Durando A; Capaldi A; Vietti-Ramus G; Alabiso O; Aglietta M
    Oncology; 2004; 66(1):38-45. PubMed ID: 15031597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility and therapeutic efficacy of weekly 1-h low-dose paclitaxel infusion for relapsed breast cancer.
    Kim R; Osaki A; Toge T
    Oncol Rep; 2003; 10(1):145-50. PubMed ID: 12469161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.